Improved survival with second-line hepatic arterial infusion chemotherapy after atezolizumab-bevacizumab failure in hepatocellular carcinoma
The superior survival outcomes and treatment responses observed in the post-ate-beva group suggest that HAIC may be an effective second-line treatment option for advanced HCC following ate-beva therapy failure. However, due to the retrospective nature and small sample size of the study, further prospective studies with larger patient populations are needed to strengthen the evidence.
Authors
- Ji H. Kim (ORCID: https://orcid.org/0000-0002-5952-957X)
- Jae-Sung Yoo (ORCID: https://orcid.org/0000-0003-3644-6701)
- Ji Won Han (ORCID: https://orcid.org/0000-0003-1456-1450)
- Ho Jong Chun (ORCID: https://orcid.org/0000-0003-4512-6152)
- Pil Soo Sung (ORCID: https://orcid.org/0000-0002-5780-9607)
- Su Ho Kim (ORCID: https://orcid.org/0000-0002-2217-009X)
- Jeong Won Jang (ORCID: https://orcid.org/0000-0003-3255-8474)
- Seung Kew Yoon (ORCID: https://orcid.org/0000-0002-4476-4868)
- Jung Suk Oh (ORCID: https://orcid.org/0000-0003-2709-4935)
- Jae Jun Lee (ORCID: https://orcid.org/0000-0002-5418-500X)
- Ji Yeon Lee
- Keungmo Yang (ORCID: https://orcid.org/0009-0005-0922-6588)
- Jong Yong Choi
Institutions
- Kyungpook National University (KR)
- The Catholic University of Korea Uijeongbu St. Mary's Hospital (KR)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-12-12
- DOI
- https://doi.org/10.3389/fonc.2024.1495321
- Citations
- 2
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.74
Funders
- National Research Foundation
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea